Trevi Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Debanjana Chatterjee from JonesTrading reiterated a Buy rating on the stock and has a $25.00 price target.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Debanjana Chatterjee’s rating is based on several positive developments for Trevi Therapeutics. The company has reported favorable outcomes from its Haduvio studies, particularly in respiratory function and drug-drug interaction, which reduce risks associated with its Phase 3 IPF program. These studies have shown no significant safety concerns, allowing for full enrollment and providing a strong foundation for upcoming regulatory discussions.
Additionally, Trevi Therapeutics is making steady progress in its RCC and ILD expansion programs. The company plans to submit a protocol for non-IPF ILD to the FDA and is preparing to initiate a dose-ranging study for RCC. The discontinuation of a competitor’s trial further reduces market competition, enhancing Trevi’s position. These strategic advancements and the company’s solid financial position contribute to the Buy rating.
In another report released on November 18, Leerink Partners also reiterated a Buy rating on the stock with a $16.00 price target.